DPP4 and Glucose intolerance: Jensen et al reported that glucocorticoid-induced glucose intolerance is associated with a progressive decline of incretin effects [19], suggesting the incretin-based therapy including the DPP-4 inhibitors may be useful for the treatment of glucocorticoid-induced diabetes.